ADC Therapeutics S.A.

5 trials 1 recruiting Commercial sponsor Merged from 2 name variants

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

1 Recruiting

4 Completed trials

8 Countries active

6 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I

Phase I (Other)

Phase III: 1 Phase II: 1 Phase I: 1 Phase I (Other): 2

Oversight events:

2 temporary halts across 1 trial

View oversight register →

100%

4 of 4 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Diffuse large B-cell lymphoma 2 Non-small cell lung cancer 1

Top IMPs

RITUXIMAB 2 ADCT-402 1 DEXAMETHASONE 1 LONCASTUXIMAB TESIRINE 1

All trials

5 total

A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer … Recruiting

2024-512089-32-00 Phase I (Other) 4 countries
A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refracto… Ended

2023-503916-33-00 Phase III 8 countries DEXAMETHASONE; LONCASTUXIMAB TESIRINE; RITUXIMAB
A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients wi… Ended

2022-501601-12-00 Phase II 2 countries ADCT-402; RITUXIMAB
A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activ… Ended

2022-500116-18-00 Phase I (Other) 2 countries
A Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activi… Ended

2022-500115-39-00 Phase I 1 country

Showing 1–5 of 5 trials

← All sponsors A–Z